Physician profile
Thomas M Santilli
NPI 1215939756
$7,909.98
in general payments reported to CMS, 2019-2025
36 companies · $61.52 in 2025
The $61.52 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,514 · 2020: $567 · 2021: $1,784 · 2022: $1,670 · 2023: $1,566 · 2024: $748 · 2025: $61.52.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,375.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,375.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $908.10 | 2019-2024 | Repatha |
| Janssen Pharmaceuticals, INC | $741.13 | 2019-2023 | Xarelto |
| Novartis Pharmaceuticals Corporation | $717.48 | 2019-2024 | |
| Pfizer INC. | $695.67 | 2019-2024 | |
| Sanofi-Aventis U.S. LLC | $633.76 | 2019-2023 | |
| E.R. Squibb & Sons, L.L.C. | $594.44 | 2019-2024 | Camzyos, Eliquis |
| Merck Sharp & Dohme LLC | $589.59 | 2021-2024 | Verquvo |
| Boston Scientific Corporation | $570.17 | 2019-2025 | Watchman Flx, Watchman Access System |
| Astrazeneca Pharmaceuticals LP | $394.90 | 2019-2024 | Farxiga, Lokelma |
| Amarin Pharma, INC. | $357.12 | 2019-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $265.39 | 2019-2024 | Jardiance |
| Astellas Pharma US INC | $218.98 | 2019-2022 | |
| Novo Nordisk INC | $158.09 | 2021-2024 | Rybelsus, Ozempic |
| Regeneron Healthcare Solutions, INC. | $94.60 | 2019 | |
| Esperion Therapeutics, INC. | $84.29 | 2021-2023 | Nexletol |
Show all 36 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Santilli listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.